TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study of nearly 200,000 adults aged 65 and older found that high-dose flu vaccination was associated with nearly 55% lower Alzheimer’s risk, compared with a 40% reduction associated with standard-dose vaccination. The observational findings do not show that the vaccine prevents Alzheimer’s disease, and the supplied report does not detail the study’s follow-up period or all methods.
A study led by UTHealth Houston researchers found that adults aged 65 and older who received a high-dose flu vaccine had a nearly 55% lower risk of developing Alzheimer’s disease than unvaccinated adults, according to the report. The analysis of nearly 200,000 people also found a 40% reduction associated with standard-dose vaccination; the results show an association, not proof that flu shots prevent Alzheimer’s.
The researchers compared Alzheimer’s outcomes among older adults who received high-dose or standard-dose influenza vaccines. The high-dose formulation was associated with a greater reduction in risk: nearly 55%, versus 40% for standard-dose vaccination. The report does not specify the study’s follow-up period or provide enough detail to interpret those percentages as absolute reductions in an individual’s chance of developing the disease.
The work, published in the journal Neurology, was led by Paul Schulz, a professor of neurology at McGovern Medical School at UTHealth Houston. The study included nearly 200,000 men and women aged 65 or older. The report says the apparent association was particularly pronounced among women, but does not provide a separate percentage or further details on that analysis.
The study follows earlier work by Schulz’s team linking influenza vaccination with lower Alzheimer’s risk. The 2022 research reported an association with a 40% reduction. The newer analysis asked whether vaccine dose might also matter. Researchers used differences in vaccination formulations among older adults to compare outcomes; the supplied account does not describe the full analytical methods or how researchers accounted for other factors that could affect Alzheimer’s risk.
A Possible Difference Between Flu Doses
The findings add a dose-specific question to research on vaccination and brain health. If the association is confirmed in further studies, it could influence how researchers evaluate the broader effects of vaccines in older people. For now, the reported percentages should not be read as evidence that a high-dose flu shot is an Alzheimer’s prevention treatment.
High-dose flu vaccines already have a practical role for older adults. The CDC recommends a higher-dose vaccine, or another preferred formulation, for people aged 65 and older because immune responses often weaken with age. The higher-dose shot contains four times as much influenza antigen as the standard-dose version. The current findings may add a reason to study the formulation, but they do not replace the established purpose of flu vaccination: protection against influenza and its complications.
The issue also has a supply dimension. The report says demand for high-dose doses can at times exceed availability, meaning some older adults receive standard-dose vaccines. The study does not establish that people who receive a standard dose should delay vaccination or seek a different product. Decisions about which vaccine is appropriate should follow current public health guidance and advice from a health professional.
Products Worth Considering
Blueair Blue Pure 211i Max Air Purifier for Large Rooms
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, 3 Modes, 2 Brush Heads and Travel Case
BowFlex Results Series SelectTech Adjustable Dumbbells (Pair)
As an affiliate, we earn on qualifying purchases.
How the Dose Question Emerged
The research question grew out of a discussion between Schulz and local public health officials, who had seen the team’s earlier vaccine research and asked whether different doses were associated with different outcomes. Schulz said he had not realized a higher-dose flu formulation was available. That conversation led the team to examine records for large numbers of older adults who had received different vaccine types.
Influenza can pose serious risks to older people, and infections may be especially concerning for those already living with cognitive impairment. The high-dose vaccine was developed to prompt a stronger immune response in older adults. Before 2022, according to the report, federal guidance did not express a preference among injectable flu vaccine formulations for adults 65 and older. The report says guidance later came to favor higher-dose or other preferred options for that age group.
Alzheimer’s disease is the leading cause of dementia. The supplied report estimates that more than 7 million Americans aged 65 and older were living with Alzheimer’s in 2025, about one in nine people in that age group, and says the figure is projected to more than double by 2050. Those estimates show why possible risk factors are being studied, but they do not change what this particular study can establish.
“The public health department had seen our vaccine research and asked if I could come down to talk to them about it. We went through the findings, and they asked if there was a difference with different dosages; I was confused.”
— Paul Schulz, senior author and UTHealth Houston neurology professor
What the Study Cannot Establish
The reported results show an association between vaccination and Alzheimer’s risk; they do not establish that a flu vaccine caused the lower risk. People receiving different vaccine formulations may differ in ways that also affect their health outcomes. The supplied report does not provide the full study design, the period over which participants were followed, the absolute risk in each group, or details on adjustments for potential confounders.
It is also unclear from the report how the researchers defined and confirmed Alzheimer’s diagnoses, how the women’s results compared numerically with men’s, and whether the findings were consistent across participant subgroups. The figures of 40% and nearly 55% are presented as relative risk reductions, but the account does not state the comparison baseline or enough statistical detail to assess their precision. Further research would be needed to test whether the dose itself explains the difference.
The findings do not show that flu vaccination can treat Alzheimer’s or reverse cognitive decline. They also do not establish that high-dose vaccination is appropriate for every individual. The report does not describe a randomized trial in which vaccine dose was assigned to participants.
Further Research on Vaccine Dose
The immediate next step is for researchers to examine the findings alongside the full methods and results in the Neurology paper, including how participants were selected, how outcomes were measured, and which other health factors were considered. Independent studies could test whether the association appears in other populations and across later flu seasons.
Researchers may also investigate possible explanations for the association, including whether differences in immune response play a role. The current report does not establish a mechanism, and it does not give a timeline for follow-up studies. Until more evidence is available, older adults should follow current vaccination guidance and discuss product choices with a clinician rather than treating the study as proof that one vaccine prevents Alzheimer’s.
Key Questions
Does a high-dose flu shot prevent Alzheimer’s disease?
The study found an association, not proof of prevention. It does not establish that receiving a high-dose flu vaccine causes a lower risk of Alzheimer’s.
What did the study report about the two vaccine doses?
Among adults aged 65 and older, standard-dose vaccination was associated with a 40% reduction in Alzheimer’s risk, while high-dose vaccination was associated with a reduction of nearly 55%. The supplied report does not give the absolute risk for each group or the follow-up period.
Who was included in the research?
The study analyzed nearly 200,000 men and women aged 65 or older, according to the report. The researchers were led by Paul Schulz of UTHealth Houston.
Should older adults choose a high-dose flu vaccine?
The CDC recommends a high-dose vaccine or another preferred formulation for adults aged 65 and older, according to the supplied report. Individuals should follow current guidance and ask a health professional which option is suitable for them; this Alzheimer’s association alone does not determine a personal vaccine choice.
Source: sciencedaily.com
